INTRODUCTION
Endoglin, also known as CD105, is an ancillary receptor of the transforming growth factor-beta (TGF-β) superfamily, and is mostly known for its abundant expression in endothelial cells and critical function in vascular development [1] [2] [3] and angiogenesis 4 .
Endoglin microvessel density is a negative prognostic factor in several solid cancers [5] [6] [7] . This receptor is a therapeutic target and TRC105, an endoglin-neutralizing antibody, is currently in phase 2 and 3 trials as an anti-angiogenic agent for the treatment of solid tumors [8] [9] [10] .
In addition to the endothelial lineage, endoglin also plays a key role in hematopoiesis. We have reported an important function for endoglin in cell fate specification and early hematopoiesis [11] [12] [13] [14] [15] , and a potential role beyond the embryonic stage is suggested by the expression of this receptor on the hematopoietic stem cell (HSC) isolated from every hematopoietic site, including the aorta-gonad-mesonephros 16, 17 , the fetal liver 18 , and the bone marrow (BM) 19, 20 , in which endoglin has been reported to identify the long-term repopulating HSC 19, [21] [22] [23] . Transcriptional profiling data of proliferating and quiescent HSCs has demonstrated endoglin to be one of the genes selectively expressed in the quiescent HSC subset 24 .
Based on this evidence pointing to endoglin as a potential regulator of HSC selfrenewal, we hypothesized that deregulated expression of this receptor could be associated with hematopoietic malignancies, in particular acute leukemias. Corroborating this hypothesis, a study based on immunohistochemistry has documented endoglin to be highly expressed in the BM of a subset of AML patients 25 . Furthermore, a gene expression profile-based study indicated that endoglin correlates with poor outcome in childhood acute lymphoblastic leukemia 26 . Nonetheless, to date the biological and Herein we report that endoglin is highly expressed in a subset of acute leukemias and that endoglin-expressing AML and B-ALL blasts are endowed with superior ability to initiate leukemia in a xenotransplantation model. Of significance, inhibition of endoglin signaling using TRC105, alone or in combination with a mild myeloablation regimen, results in inhibition of AML and B-ALL development and progression, suggesting endoglin as a potential target for the treatment of these diseases.
MATERIAL AND METHODS

Leukemic cell lines and primary samples
SEMK-2, Nalm-6, RS4;11, Raji and Jurkat cell lines were maintained in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gemini) and 1% penicillin/streptomycin. HL-60 cells, from ATCC (CCL-240), were maintained in IMDM (Gibco) containing 20% FBS and 1% penicillin/streptomycin. Single cell suspension cultures were maintained in a humidified incubator at 37°C in an environment of 5% CO2.
De-identified, diagnostic cryopreserved mononuclear cells from bone marrow, peripheral blood or apheresis, as detailed in Table 1 , and sera samples from AML and ALL patients analysis. At least 100,000 events were acquired. FlowJo software was used for analysis (Tree Star Inc.). For sorting, blasts were purified based on CD105 or CD45 expression.
Mice and xenograft leukemia model
All experiments were approved by the University of Minnesota Institutional Animal Care and Use Committee. Female NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ; Jackson Laboratories) mice were 7-9 weeks of age at the time of injection. Sub-lethally irradiated (2.0-2.5 Gy) NSG mice were intravenously (IV) injected with 5x10 
Treatment with TRC105 in a xenograft model
TRC105 is an IgG monoclonal antibody specific for endoglin produced by TRACON Pharmaceuticals. At day 2 or day 30 after injection of AML or ALL blasts, mice were randomly divided into 3 groups: i) untreated, ii) TRC105 (2mg/kg IV, every 3 days), and iii) IgG isotype control antibody (Life Technologies) in a similar manner. Studies involving chemotherapy consisted of Cyclophosphamide (90mg/kg IP, once a week) for ALL and Cytarabin (100mg/kg IP, once a week) for AML, alone or in combination with TRC105. PB was analyzed monthly for the presence of human CD45. BM and spleen were analyzed at the end of the study.
Measurement of soluble endoglin (sEng)
Enzyme-linked immunosorbent assay (ELISA) for human Endoglin/CD105 (R&D Systems) was performed on supernatant of leukemic cell cultures, human plasma and serum of leukemic mice. Cultures of NALM-6, SEMK-2 and HL-60 cells were started at 2x10 5 cells/ml and supernatant was collected 4 days later.
Western Blot
Cells were lysated in RIPA Buffer, containing antiproteolytics. MMP-14 (EP1264Y, 1:1000, Abcam) and Gapdh (1:3000, Abcam) were diluted in Primary Antibody Signal Boost Immunoreaction Enhancer (Calbiochem). ECL peroxidase-labeled anti-mouse and anti-rabbit antibodies (GE Biosciences) were diluted at 1:10,000 with 5% BSA in 1X TBS-Tween20.
Statistical analysis
Statistical analysis was determined by the comparison of means using unpaired Student's t test (for 2 groups) or one-way ANOVA (three groups). Paired Student's t test was used Figure 1A -B), as described 27 . Further sub-fractionation of BM and cord blood based on CD38 expression revealed that CD105 is present in both fractions, but abundantly on the CD34 We next determined whether CD105 would be distinctively expressed in samples from patients with AML and precursor B-ALL. Nine de-identified primary samples from B-ALL and AML patients were evaluated ( Table 1) . The blast population was gated based on side scatter (SSC) and low/intermediate expression of CD45, and then analyzed for 8 the expression of CD34 and CD38 to confirm the immature phenotype [29] [30] [31] , CD19 or CD117 (to confirm B-ALL or AML phenotype, respectively), and CD105 (supplemental Figure 2 and Table 1 ). CD105 was highly expressed on the majority of B-ALL blasts, and varying from 47.5% to 98.5% in AML blasts (Table 1 and Figure 1B ), indicating that CD105 is expressed on myeloid and B-lymphoid leukemic blasts.
CD105 + blasts have superior in vivo leukemogenic activity
To determine whether CD105 is differentially expressed by cells with leukemia-initiating potential, we used FACS to isolate both AML ( Figure 1C ) and ALL ( Figure 1F 
Inhibition of endoglin reduces leukemogenic activity
Next we investigated whether inhibiting endoglin function using the TRC105 antibody would affect leukemia development. Two days after infusion with AML or ALL blasts, mice were randomly divided into 3 groups: treatment with TRC105 or IgG isotype control, or untreated, as outlined in Figure 2A . Figure 8B ). However by 12 weeks, the BM of both groups contained equivalent high numbers of human CD45 (supplemental Figure 8B ).
In the case of ALL, our results showed that treatment with TRC105 has no effect on leukemia progression when administered after disease has been established. Four weeks after beginning treatment, all groups displayed very high numbers of human CD45 + blasts in the PB (> 95%; Figure 3E -F). Massive leukemic cell infiltration was found in the BM and spleen of both groups (supplemental Figure 8E) , and accordingly, 12 no differences in body weight or survival between TRC105-and IgG isotype-injected groups (supplemental Figure 8F and Figure 3G , respectively).
Levels of soluble endoglin (sENG) correlate inversely with effectiviness of TRC105
Based on these results, we hypothesized that the limited effect in the ALL model could be due to expression of the soluble form of endoglin (sENG), which would titrate the TRC105 antibody, thus limiting its ability to bind to membrane-bound endoglin (mENG) on leukemic cells (Fig. 4E) . We began by determining the levels of sENG in the plasma of AML and ALL patients at the time of diagnosis and discovered that sENG was significantly higher in the plasma of ALL patients compared to AML patients ( Figure   4A ). Next we measured sENG in the serum of mice engrafted with human AML or ALL blasts and treated with TRC105. 12 weeks after transplantation, sENG could be detected in the serum of mice transplanted with ALL cells, and was significantly decreased in the group treated with TRC105 ( Figure 4B ). However, at the same time point, no significant detection of sENG was found in the serum of mice injected with AML cells ( Figure 4B ). This is in agreement with Al-Mowallad et al. 32 , who reported plasma levels for CD105 to be elevated in children with acute lymphoblastic leukemia.
To date, soluble endoglin/CD105 is mostly associated with microvessel density and angiogenesis 32 , and thus, it is unknown whether leukemic cells may be a source of sENG. To address this question, we quantified levels of sENG on supernatant of different subtypes of leukemic cell line cultures. We found that higher levels of sENG are present in the supernatant of the lymphoblastic pre-B cell lines Nalm-6 and SEMK-2 when compared with the promyeloblastic HL60 cell line ( Figure 4C ). This interesting finding points to differential cleavage of mENG in ALL compared to AML. Accordingly, Matrix
Metalloproteinase-14 (MMP-14), which has been reported as the mediator of endoglin 13 shedding 33 , is distinctively expressed in the lymphoblastic pre-B cell line, whereas not detected in HL60 myeloid cells (Fig. 4D ).
This data supports the notion that the soluble form of endoglin could mitigate the therapeutic activity of TRC105 by preventing the antibody from binding to the cell surface, as outlined in Figure 4E .
Effect of TRC105 combined with mild myeloablation
Since it is unlikely that TRC105 would be used as a monotherapy in AML and B-ALL, we next determined whether TRC105 could potentiate the effect of chemotherapeutic agents using a mild regimen. Once disease had been established, we began therapy with TRC105 (same manner as before) in combination with Cytarabin (AraC) for AML and Cyclophosphamide (CPA) for ALL, which were injected only once a week. In the case of AML, AraC alone slowed down disease progression during the first 2 weeks, but this effect did not persist (Supplemental Fig. 9 ). On the other hand, combined therapy with TRC105 significantly reduced the levels of leukemic cells in the PB (2-fold; Supplemental Fig. 9 ).
In ALL, both CPA alone or in combination with TRC105 suppressed leukemia development, but effect of combined therapy was more effective sooner ( Fig. 5A and supplemental Fig. 10) . Remarkably, BM analysis at 2 months of treatment revealed the lowest levels of leukemia infiltration in the TRC105+CPA cohort (1.7±0.5 vs. 29.1±15.5 in CPA alone), whereas untreated and TRC105 alone cohorts were nearly completely positive for human CD45 (Fig. 5B-C) . Consistently, sENG was detected at very high levels in the serum of untreated ALL mice, and at lower levels in the TRC105 group, as observed in Fig. 4B , but most importantly, no significant detection could be observed in CPA and CPA+TRC105 cohorts (Fig. 5D ). These findings demonstrate that the inhibitory 14 effect of sENG can be circumvented by suppressing tumor burden, resulting in the combined therapy having potent anti-leukemic activity (Fig. 5B-C) .
.
DISCUSSION
Novel therapeutic targets for acute leukemia are urgently needed. Successful treatment of acute leukemia remains a clinical challenge due to the relatively heterogeneous responses to the current standard therapy and the associated toxicity, in particular in the elderly patient population 34, 35 . AML is associated with a 5-year overall survival of less than 50%, and between 10% and 40% of newly diagnosed patients with AML do not achieve complete remission with intensive therapy 36, 37 . For ALL, although significant progress has been made in the last decade, in cases of refractory or relapsed ALL, second line chemotherapy has shown poor effect, rarely resulting in long-term survival 38, 39 . Thus, there is a critical need for new therapeutic options. Monoclonal antibodies are promising agents since they deliver their therapeutic effects with minimal toxicity 39, 40 .
Based on the expression of ENG on HSCs, we investigated whether ENG might also be expressed on leukemic blasts. We found the majority of B-ALL and AML blasts express ENG, and that leukemia-forming activity is detected uniquely in the ENG + fraction of B-ALL, whereas in AML, this activity is enriched in this fraction, as leukemia develops faster when ENG + cells are injected. Thus, removing ENG + blasts delays AML disease onset (Fig. 1D-E) , but does not prevent it, as observed for B-ALL (Fig. 1G-H Similar suppressive effect was observed in the BM by 8 weeks, but TRC105 alone was not sufficient to avoid BM disease since by 12 weeks, there was no longer difference between TRC105-treated and IgG control group. We believe this may be related to the antibody half-life and epitope occupancy. This warrants further studies, including testing therapeutic effect in additional leukemic samples as well as different treatment regimens.
Of note, the original primary AML sample (A0032) used in our xenotransplantation assays, comes from a case of CML transformed, with blast crises, characterized by a complex cytogenetic profile (t (1;3) ;del(5);-7;idem;t(1;17)), with deletion on chromosomes 7, which has been reported to be associated with poor prognosis and resistance to standard therapy 41 . Our encouraging results suggest the therapeutic benefit of targeting CD105 in AML with TRC105. This is underscored by the fact that phase I and II trials of TRC105 in solid tumors have shown it to be well tolerated at clinicially relevant doses [8] [9] [10] . When the maximum tolerated dose (MTD) was exceeded, at 15 mg/kg every week, hypoproliferative anemia has been reported 9 . This side effect was easily monitorable, reversible and treatable without adverse sequelae 9 , however this would be important to monitor closely in leukemia patients receiving TRC105.
The concept of antibody targeting for malignancies, including acute leukemia, is well established 39, 42 . Several antigens have been identified as potential targets in AML.
The best known is CD33, for which an anti-CD33 monoclonal antibody conjugated Gemtuzumab ozogamicin (GO) was approved by the FDA for the treatment of relapsed However, these monoclonal antibodies showed limited efficacy in established disease treatment models [44] [45] [46] , in contrast to TRC105, which effectively prolonged survival in AML, even when treatment started after establishment of truthful leukemia (20% of peripheral blood).
In the case of the ALL cohort, we observed only modest effects of TRC105 treatment. At week 8, massive leukemic cell infiltration was found in the PB, BM and spleen of all experimental groups. It seems likely that this limited effect of TRC105 in the ALL model could be due to sENG, which arises from the proteolytic cleavage of the receptor extracellular domain by MMP-14 33, 47 . sENG has been shown to represent a biomarker for many solid cancers [48] [49] [50] . Our results show for the first time shedding of sENG by lymphoblastic pre-B cells, which correlated with MMP-14 expression, indicating that this process is not restricted to angiogenic cells. Higher levels of sENG were detected in the plasma of B-ALL patients when compared to AML counterparts, indicating differences in ENG shedding between ALL and AML. Consistent with this result, minimal levels of sENG were detected in the serum of AML-injected mice, while ALL-engrafted mice showed high levels of sENG, which were significantly decreased in the TRC105-treated cohort. These results support the premise that the soluble form of this receptor could be interfering with efficacy of TRC105 therapy by serving as a soluble decoy, preventing TRC105 from binding to the surface of target leukemic cells.
Nevertheless, combined therapy with CPA circumvented this problem, and provided the most potent anti-leukemic activity. It is also plausible to hypothesize that in the setting of , it is therefore possible that efficacy might be even better in the immnocompetent setting. Because TGF-β, a well-established ligand for endoglin 52 , is also known for its critical role in HSC regulation [53] [54] [55] , we hypothesize that TRC105 may be functioning by modulating TGF-β signaling.
In conclusion, our results show that CD105 is a biomarker for acute leukemia that (E) Schematic representation outlining the effect of sENG on TRC105 treatment. In AML, which is characterized by low levels of sENG, the monoclonal antibody TRC105 is free to bind to the membrane form of endoglin (left panel). However, in ALL (right panel), which exhibits high levels of sENG, TRC105 is decoyed, resulting in less TRC105 available to bind to mENG, and thereby less therapeutic effect. 
